DXCM DexCom, Inc.
$78.56▼ -0.01%
Healthcare
Other
After hours
$78.56▲ +0.00%
Oct 27, 4:14 PM ET
Volume 5.16M
Avg Volume (10D) 5.09M
Key Metrics & Fundamentals
Market Cap
$29.65B
P/E Ratio
31.2
Div Yield
0.00%
52W Range
54.11 - 92.59
% vs 50 MA
-9.07%
% vs 200 MA
5.57%
RSI-14
34.3
MACD Histogram
-0.7800
Beta (1Y vs SPY)
0.63
Free Cash Flow
$184.50M
Gross Rev
$1.31B
Gross Profit
$830.00M
EBITDA
$388.70M
COGS
$478.40M
Operating Exp
$511.70M
Operating Income
$318.30M
EBIT
$318.30M
Pretax Income
$317.50M
Net Income
$249.10M
EPS (Diluted)
0.64
Price & Volume History
Loading chart…
Recent News
DexCom Gears Up to Report Q3 Results: How to Play the Stock?
Zacks · Oct 26, 2026 12:59 PM ET
Leerink Partners Adjusts Price Target on DexCom to $87 From $94
MT Newswires · Oct 26, 2026 6:52 AM ET
Here Are This Week’s Biggest Losers After the Tech Selloff
The Wall Street Journal · Oct 23, 2026 9:36 AM ET
Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM?
Simply Wall St. · Oct 21, 2026 9:17 PM ET
Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive?
Insider Monkey · Oct 20, 2026 12:31 PM ET
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
Zacks · Oct 20, 2026 9:50 AM ET
Global Wearable Electronics Market Report 2026-2036 | AI, Extended Reality, and Digital Health Drive New Growth and Investment Opportunities
GlobeNewswire · Oct 19, 2026 5:29 AM ET
Vaso Stock Surges 149% in a Year: What's Behind the Rally?
Zacks · Oct 16, 2026 12:52 PM ET
NEJM study supports CGM use for people with diabetes who don’t take insulin
MedTech Dive · Oct 15, 2026 11:53 AM ET
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
Business Wire · Oct 14, 2026 5:10 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See DXCM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.